Comparison of Platelet Function and Morphology in Patients Undergoing Percutaneous Coronary Intervention Receiving Bivalirudin Versus Unfractionated Heparin Versus Clopidogrel Pretreatment and Bivalirudin

American Journal of Cardiology

Volumn 100, Issue 3, 2007, Pages 417-424

  Anand, Sunil X ^a   Kim, Michael C ^a   Kamran, Mazullah ^a   Sharma, Samin K ^a   Kini, Annapoorna S ^a   Fareed, Jawed ^c   Hoppensteadt, Debra A ^c   Carbon, Frank ^a   Cavusoglu, Erdal ^b   Varon, David ^d   Viles Gonzalez, Juan F ^a   Badimon, Juan J ^a   Marmur, Jonathan D ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CD40 LIGAND; CLOPIDOGREL; HEPARIN; HIRULOG;

ADULT; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MALE; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTE MEMBRANE; THROMBOCYTE STRUCTURE; VOLUNTEER;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; BLOOD PLATELETS; CD40 LIGAND; CORONARY ANGIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPARIN; HIRUDINS; HUMANS; MALE; MICROSCOPY, ELECTRON, SCANNING; MIDDLE AGED; PEPTIDE FRAGMENTS; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; TICLOPIDINE;

EID: 34447645830     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.02.106     Document Type: Article

References (21)

1. Lincoff A.M., Bittl J.A., Harrington R.A., Feit F., Kleiman N.S., Jackman J.D., Sarembock I.J., Cohen D.J., Spriggs D., Ebrahimi R., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289 (2003) 853-863
2. Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K., Malmberg K., Rupprecht H., Zhao F., Chrolavicius S., Copland I., and Fox K.A. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
3. Robson R., White H., Aylward P., and Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther 71 (2002) 433-439
4. Osende J.I., Fuster V., Lev E.I., Shimbo D., Rauch U., Marmur J.D., Richard M., Varon D., and Badimon J.J. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. Circulation 103 (2001) 1488-1491
5. Varon D., Lashevski I., Brenner B., Beyar R., Lanir N., Tamarin I., and Savion N. Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am Heart J 135 suppl (1998) S187-S193
6. Fuster V., Badimon L., Badimon J.J., and Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 326 (1992) 242-250
7. Fuster V., Badimon L., Badimon J.J., and Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 326 (1992) 310-318
8. Weitz J. The thrombin-specific anticoagulant, bivalirudin, completely inhibits thrombin-mediated platelet aggregation. Am J Cardiol 88 (2001)
9. Helft G., Osende J.I., Worthley S.G., Zaman A.G., Rodriguez O.J., Lev E.I., Farkouh M.E., Fuster V., Badimon J.J., and Chesebro J.H. Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol 20 (2000) 2316-2321
10. Storck J., Kusters B., and Zimmermann E.R. The tethered ligand receptor is the responsible receptor for the thrombin induced release of von Willebrand factor from endothelial cells (HUVEC). Thromb Res 77 (1995) 249-258
11. Goto S., Salomon D.R., Ikeda Y., and Ruggeri Z.M. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets. J Biol Chem 270 (1995) 23352-23361
12. Savage B., Sixma J.J., and Ruggeri Z.M. Functional self-association of von Willebrand factor during platelet adhesion under flow. Proc Natl Acad Sci U S A 99 (2002) 425-430
13. Hung D.T., Vu T.K., Wheaton V.I., Ishii K., and Coughlin S.R. Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation. J Clin Invest 89 (1992) 1350-1353
14. Kahn M.L., Nakanishi-Matsui M., Shapiro M.J., Ishihara H., and Coughlin S.R. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 103 (1999) 879-887
15. Leger A.J., Jacques S.L., Badar J., Kaneider N.C., Derian C.K., Andrade-Gordon P., Covic L., and Kuliopulos A. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 113 (2006) 1244-1254
16. Salzman E.W., Rosenberg R.D., Smith M.H., Lindon J.N., and Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 65 (1980) 64-73
17. Xiao Z., and Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 97 (1998) 251-256
18. Sobel M., Fish W.R., Toma N., Luo S., Bird K., Mori K., Kusumoto S., Blystone S.D., and Suda Y. Heparin modulates integrin function in human platelets. J Vasc Surg 33 (2001) 587-594
19. Goto S., Tamura N., Eto K., Ikeda Y., and Handa S. Functional significance of adenosine 5′-diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate. Circulation 105 (2002) 2531-2536
20. Keating F.K., Dauerman H.L., Whitaker D.A., Sobel B.E., and Schneider D.J. The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. Coron Artery Dis 16 (2005) 401-405
21. Viallard J.F., Solanilla A., Gauthier B., Contin C., Dechanet J., Grosset C., Moreau J.F., Praloran V., Nurden P., Pellegrin J.L., Nurden A.T., and Ripoche J. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood 99 (2002) 2612-2614